| INTRODUCTION
Overweight and obesity currently affects~62% of the UK adult population 1 and is linked to many chronic diseases such as cardiovascular disease (CVD), diabetes and cancer. The significant morbidity and mortality associated with overweight and obesity imposes a major burden on the healthcare system. The UK Foresight report estimated that, in 2007, the annual direct costs to the National Health Service (NHS) of treating overweight and obesity, and related morbidity, were approximately £4.2 bn in England alone 2 and, more recently, the McKinsey report has estimated the global burden as equivalent to $2 tn annually. 3 Weight loss, even when modest or unsustained long-term, has been shown to reverse some of the effects of overweight and obesity, and in turn reduce the risk of chronic diseases such as type 2 diabetes 4 and CVD. 5, 6 Weight loss interventions include lifestyle interventions (diets to reduce energy intake, increased exercise or physical activity, or their combination) as well as pharmaceutical and bariatric surgical interventions. Just as the extent of weight loss differs between interventions, so too do the costs. For example, bariatric surgery, which involves invasive surgery and hospitalization, is initially much more expensive than pharmaceutical therapy, which is in turn more expensive than most lifestyle interventions. Whilst cost-effectiveness analyses to investigate the cost-effectiveness of specific interventions in the prevention and treatment of obesity and its related diseases have been undertaken, the cost-effectiveness of weight loss (irrespective of the type of intervention used) has not been evaluated as an integrated whole. In the present study, we aim to determine the amount of monies available, from an English NHS perspective, for weight loss interventions to be considered costeffective in the prevention of CVD, with a particular focus on interventions that result in moderate (5 to <10%) weight loss. from CVD or die from other non-cardiovascular causes. All events were considered to occur halfway through an annual cycle.
| METHODS
An
| Transition probabilities

| Primary CVD
The annual risk of a primary CVD event was determined using the 
| Secondary CVD
The risks of secondary events were sourced from a Health Technology Assessment report for an economic evaluation of statins for the prevention of coronary events, 8 which provided annual transition probabilities by age and sex. These risks were dependent on the type of primary CVD event (e.g. CHD or stroke event), and included secondary non-fatal myocardial infarction, non-fatal stroke, fatal myocardial infarction and fatal stroke.
| Death from other causes
The risk of dying from other causes was determined using data from the Office for National Statistics 2010 for England and Wales only, 9 calculated as the difference between all-cause mortality and circulatory deaths. This was stratified by age and sex.
| Population
Individual subject data were gathered from the Health Survey for 
| Effect of weight loss
Data on the effect of weight loss on CVD events as such are limited.
There is, however, extensive evidence on the impact of interventions that cause weight loss on cardiovascular risk factors. We recently conducted a systematic review and meta-analysis on the effect of interventions that cause weight loss on cardiovascular risk factors at different time points (6 to <12 months, 12 to <24 months and ≥24 months). 10 We excluded bariatric surgery, as this causes extreme and rapid weight loss, is only appropriate in severely obese individuals and only a very small minority are able to access it. 11 In our model, we only included the risk factor effects present in the Framingham risk prediction algorithm (systolic blood pressure, total cholesterol and HDL cholesterol). The effects of interventions that cause weight loss on cardiovascular risk factors were stratified by different degrees of percentage weight loss (0% to <2.5%, 2.5% to <5%, and 5% to <10%). Sub-analyses assessed the effect of percentage weight loss on cardiovascular outcomes, assuming 100% compliance. Input data, however, came from our meta-analysis, where the percentage weight loss encapsulated participants that did not have 100% compliance or success with weight loss interventions (see Table 1 for input values). Interventions which extended beyond the 24-months time point were typically 24 to <36 months in duration. For cycles in the model after 36 months (4-10 years), both a best-and worst-case scenario were explored. In the first instance, the effects of weight loss on cardiovascular risk factors were set to zero, that is, there were no subsequent effects associated with the weight loss on cardiovascular risk factors (a conservative estimate). In the second analysis, the effects of weight loss on cardiovascular risk factors were assumed to remain the same throughout the 10-year period as those observed at 24 months.
| Utilities
All individuals in the model were assigned a quality-of-life value or utility according to their BMI, which was age-and sex-specific. If they were deemed to have a cardiovascular event, the utility decrement associated with the cardiovascular event was then applied ( Table 2 ). 
| Costs
The costs of cardiovascular events were taken from the ScHARR cost-effectiveness model and were based on a thorough review of the most recent and appropriate costing information. 8 They are summarized in Table 2 and costs were discounted at 3.5% per annum.
| Outcomes
The outcomes of interest we studied were the number of QALYs gained and the potential monies available for prevention strategies, provided the incremental cost effectiveness ratios (ICERs) met arbitrary limits set out in terms of UK pounds per year per QALY saved.
We calculated ICERs by comparing the difference in net costs between treatment (weight loss) and no treatment (control), divided by the difference in QALYs lived by each cohort. The arbitrary threshold for ICERs is between £20 000 and £30 000. 13 We used both threshold limits to determine the potential monies available for prevention strategies over 10 years.
| RESULTS
A When weight loss was stratified by percentage weight loss (0% to <2.5%, 2.5% to <5%, 5% to <10%), the number of cardiovascular events prevented, the number of QALYs saved and the potential monies available increased with increasing weight loss (Table 3 ). In line with the results seen in the main analysis, when the treatment effects after 36 months were set to maintain 24 to <36 months outcomes, the number of CVD events prevented, number of QALYs saved and potential monies available were greater than when they were set to the conservative scenario of no sustained weight loss effects.
Applying the effects of weight loss on CVD risks to an older population of adults aged 40 to 74 years, prevented more cardiovascular events than when the whole population was included (Table 3) .
Applying the effects of weight loss to only those who were overweight prevented slightly less events than when both overweight and obese subjects were included, but with lower annual permitted expenditures ( Table 4 ). The reverse was seen when the effects of weight loss were applied to only those who were in the obese category.
| DISCUSSION
Weight loss has been shown to reduce cardiovascular risk factors and events and increase the number of QALYs. 10 In England the provision of short-term, non-clinical weight management (so-called Tier 2) services is commissioned at a cost of between <£50 and £400 (most frequently reported at £100/patient) [14] . Tier 3 services represent more complex interventions, that are clinically led and targeted at those with severe and/or complex obesity, but these are scant.
Where they exist, the cost is reported to be >£400/patient. 14 We have explored what sums of money could be spent on weight loss interventions that would meet NICE criteria for cost efficacy. 15 Interventions that cause weight loss could potentially gain between 15 and 50 QALYs for a population of 1000 individuals aged 30 to 74 years who were overweight/obese and free of existing CVD, over 10 years. According to the arbitrary thresholds of affordability equal to £20 000 to £30 000 per QALY gained, between £34 and £142 could potentially be spent per person each year for up to 10 years on weight loss interventions. When weight loss was stratified by percentage weight loss (0% to <2.5%, 2.5% to <5%, 5% to <10%), greater reductions in weight resulted in more QALYs gained and therefore the potential for greater financial inputs for prevention strategies. As expected, when the effects after 36 months were constant and remained the same as at 24 to <36 months, the results were more pronounced than when the effects after 36 months were set to null; however, this was not apparent when the effects of 5% to <10% weight loss were considered. This finding may simply reflect the absence of data obtained in the systematic review for the long-term effects of sustained 5%
to <10% weight loss rather than something specific to this greater weight loss achievement. Furthermore, this scenario is likely to be overly conservative as there is clear evidence from a number of lifestyle intervention programmes that benefits of diabetes prevention persist in the long term. 16 Unsurprisingly, analysis of the older age group (age 40-74 years)
showed that a greater number of cardiovascular events could be prevented when the benefits after 24 months were maintained, compared with the whole population of 30-to 74-year-olds. The number of QALYs saved was also greater. Because CVD events in younger age groups are fewer than in older adults, this finding may change if whole lifetime benefits (rather than a 10-year follow-up) were to be modelled. Furthermore, if adults aged ≥75 years were included, then their far higher absolute risk could potentially have enhanced the benefits over a subsequent decade of weight loss and reduced cardiovascular risk; however the Framingham risk prediction algorithm excluded those aged >74 years.
Our model has shown that the potential monies available for weight loss strategies in the prevention of CVD can range from £27
to £134 per person per year for 10 years, dependent on the population, amount of weight loss, long-term effects of weight loss, and cost-effectiveness threshold employed. Whilst many intervention strategies have been reported as far dearer than this, 17, 18 this amount is within current spending on Tier 2 services in England.
Our findings therefore support "investment" in making access to treatment programmes more readily available, even if they produce "only" modest weight losses of~5%, and even if this weight is not sustained in the long term. This may include relatively cheap community-wide wellness programmes, such as free or subsidized exercise classes. 19 As the risk of overweight and obesity escalates with age there will be greater justification for applying rather more expensive interventions for this older portion of the population.
Several analyses have been conducted on the benefits and cost efficacy of pharmaceutical interventions. 20, 21 Benefits are wider than just those for the cardiovascular effects analysed in the present modelling exercise. Interestingly, the application of "stopping rules"
(i.e. discontinuing medication) in non-or poorly responding patients is now widely included in the regulatory approval process and can enhance safety, efficacy and cost efficacy. Regulatory measures that aim to change the nature of societal eating patterns by imposing checks and taxes on advertising of inappropriate foods and drinks, taxing sugary drinks and fast foods are all capable not only of raising government revenue but, if they allow even modest weight loss on a population basis, important cost savings for the health services.
Purely on a cardiovascular basis the benefits are likely to be great, provided the costs of implementation through regulatory measures Potential monies available for prevention of CVD to ensure cost savings for interventions that cause weight loss and its effect on cardiovascular risk factors is set out assuming either only short-term benefits for the first 36 months of weight loss (nil effects) or continuing benefits for the whole 10-year period (same effects).
b Any weight loss represents any weight loss (0% to >10% change in body weight); nil effects represents zero effect of weight loss on cardiovascular risk factors after 3 years; same effects represents same effects of weight loss on cardiovascular risk factors after 3 years as at year 3. Potential monies available for prevention of CVD to ensure cost savings for interventions that cause weight loss and its effect on cardiovascular risk factors is set out assuming either only short-term benefits for the first 36 months of weight loss (nil effects) or continuing benefits for the whole 10-year period (same effects).
b Nil effects represent a zero effect of weight loss on cardiovascular risk factors after 3 years. are small for governments. If these and additional measures which reduce hypertension and population lipid levels (e.g. by continuing to reduce salt 22 and saturated fat intakes) are implemented, the benefits in reducing CVD will be amplified.
A number of features of the present study limit its robustness.
First, although the Framingham algorithms are widely accepted, they do not always predict cardiovascular events in other populations accurately. Furthermore, these algorithms generated from a general population in practice underestimate CVD risk in some higher-risk populations, such as those with diabetes. It is also clear that, without long-term data on the overall impact of weight loss interventions on cardiovascular events, it is unclear whether the benefits are cumulative, or progressively increase or decrease; therefore, in the present analyses we performed an assessment of the impact of interventions that cause weight loss on cardiovascular risk over an extended duration, on both a best-and worst-case basis. When we assumed conservatively that there were no further benefits after 36 months of weight loss, this worst-case scenario limited the scale of the benefit.
However, a recent study 23 found that any weight loss, even if not sustained, was associated with decreases in carotid intimal thickness and improvements in the cardiovascular risk factor profile, suggesting that weight loss, at any age in adulthood, is worthwhile and could result in long-term cardiovascular benefit. This so-called "memory effect" of weight loss has been well demonstrated in a number of diabetes prevention programmes [24] [25] [26] [27] and suggests that interventions that are not sustained may still have profound and long-lasting value.
A further limitation of our model pertains to our model population, who may not be representative of the general UK population.
Whilst our population was sourced from a national health survey, our rates of smoking were lower than observed in the larger Health Survey for England dataset, the General Lifestyle Survey and the Smoking Tookit Study; 28 this may reflect some selection bias as individuals with any missing variable data were excluded. Our population, therefore may be "healthier" than the general population. Employing a "lower" risk population in our model could result in an underestimation of the true cost-effective benefits of weight loss interventions in the UK.
Finally, the effects of weight loss on other outcomes were also not included. Weight loss has been shown to be beneficial for other outcomes such as cancer, osteoarthritis and depression. [29] [30] [31] [32] The reduction in disease would not only decrease the costs associated with treatment, but also improve the quality of life for the individual.
The omission of other weight loss outcomes in our model further adds to the conservative estimate of the true effectiveness and costeffectiveness of weight loss interventions in the UK.
In conclusion, the findings from the present study show the circumstances under which interventions that cause weight loss may be cost-effective in the prevention of CVD. The individual annual financial allowance for selective cardiovascular preventive measures from weight loss alone is small to gain savings in healthcare costs, but still higher than is being spent by public health and clinical commissioning groups at present. However, with such a large proportion of the population overweight or obese, and with CVD still the major cause of death and disability, the need for population-wide cheap societal interventions to limit weight gain and encourage weight loss are particularly important and could substantially reduce health services costs.
